The stock climbed to $24.99 following the news, extending a strong rally that has seen Edgewell shares gain 33% since the start of the year. While the company and Yellow Wood representatives declined to comment on the internal deliberations, the rejection signals a board strategy focused on higher valuations despite the unsolicited interest from the private-equity firm. Edgewell remains a prominent player in the personal care sector, and this rejection underscores the company's current resistance to acquisition at the proposed price point.